thumbnail image
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
broken image
  • OncoSeekTM

    Low-cost early cancer detection service

    broken image

    OncoSeekTM was established using artificial intelligence (AI) to distinguish cancer from non-cancer cases by calculating the probability of cancer (POC) index based on the quantification results of seven protein tumor markers (PTMs) and clinical information including gender and age of the subjects. And prediction the possible affected tissue of origin (TOO) who has been detected with cancer signal.

    broken image

    A large cohort study (nearly 10,000 participants) confirmed that OncoSeek significantly outperformed the conventional clinical method, representing a novel blood-based test for multi-cancer early detection (MCED) which is a non-invasive, easier, efficient, and robust approach. The data showed that the conventional clinical method relied only on a single threshold for each PTM which would make a big problem that was when combining the result of those markers, the false positive rate would accumulate as the number of tests increased. Nevertheless, AI algorithms play a key role in OncoSeek approach, which makes it possible to do multiple cancer screenings based on PTMs. Moreover, this method can accurately trace the origin of cancer which facilitates the follow-up diagnostic workup.

    broken image
  • Specifications

    ◉ Indicated subjects: AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1

    ◉ Sample requirement: 8ml peripheral blood

    ◉ TAT: 5 working days

  •  

    How it works

    broken image

    Customer order

    Customers can place orders through SeekIn official website or local agents

    broken image

    Blood-draw

    8 ml venous peripheral blood collected in cell-free DNA BCT and can be stably stored at room temperature for 7 days

    broken image

    Testing

    Detection by Roche cobas e411 instrument

    broken image

    Reporting

    The test results will be ready in about 5 workdays after your blood draw arrived at central lab

  • Please review the instructions to gain a better understanding of OncoSeek™ and assess whether it meets your needs.

    Downlod the Instructions

Navigation

Technology   

SeekInCare

SeeInCure

SeekInClarity

OncoSeek

Research

Contact Us

10320 Camino Santa Fe, Suite G

San Diego, CA 92121

United States

info@seekincancer.com

© 2024 SeekIn Inc.

All Rights Reserved.

Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More